| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9a39a1419bb9d07dce104ba57644e35 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2018-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f4be7f7786c009cedb6bd93e64c0935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b10e9b3bf800136950638fc84bfa733f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b07c7df47c837cd6645b255bc02ea4c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26afb217765f2a1ad410d7299a7ba7fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81b658e6d6fff081de646b79901141fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d4854092ef96686b97d55a270748456
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c15a4804c59cf7a03310f613a39f32d |
| publicationDate |
2019-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2018256392-A1 |
| titleOfInvention |
Anti-PD-L1 antibody and use thereof |
| abstract |
Disclosed are fully human anti-PD-Ll antibodies and their corresponding applications. Fully human antibodies are capable of specifically binding to human PD-L1. Antibodies were obtained by employing a yeast display library-based screening technique and also by affinity maturation to further improve their affinity for PD-L1. The fully human anti-PD-Ll antibodies disclosed show good specificity, affinity and stability. They are capable of enhancing T cell activity by binding to activated T cells, while significantly inhibiting tumor growth. Disclosed fully human anti-PD-Ll antibodies can be used in the diagnosis and treatment of PD-Ll-related cancers and other associated diseases. |
| priorityDate |
2017-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |